ReNeuron Group (LON:RENE) posted its quarterly earnings results on Thursday. The company reported GBX (0.30) ($0.00) earnings per share for the quarter, Bloomberg Earnings reports. The company had revenue of GBX 200 million during the quarter. ReNeuron Group had a negative net margin of 32,825.00% and a negative return on equity of 27.66%.

Shares of ReNeuron Group (RENE) opened at GBX 2.01 ($0.03) on Friday. ReNeuron Group has a one year low of GBX 1.58 ($0.02) and a one year high of GBX 3.20 ($0.04).

Several research analysts have recently commented on RENE shares. N+1 Singer reiterated a “corporate” rating on shares of ReNeuron Group in a research note on Monday, October 9th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 13 ($0.17) target price on shares of ReNeuron Group in a research note on Thursday, November 9th.

COPYRIGHT VIOLATION NOTICE: “ReNeuron Group (RENE) Announces Earnings Results” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at

About ReNeuron Group

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).

Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with's FREE daily email newsletter.